Rion Co., Ltd.

2026/10/29 11:49 Updated
Market Cap: $252.5M (¥39.9B)
Stock Price: $20.48 (¥3,235)
Exchange Rate: 1 USD = ¥157.98

Rion Co., Ltd. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

In the second quarter of the fiscal year ending March 2027, all three business segments recorded revenue growth. Revenue was 14,284 million yen, operating income 2,150 million yen, ordinary income 2,185 million yen, and interim net income 1,577 million yen. For the second half, a substantial revenue increase is expected from the particle measurement instruments segment, while hearing aids and medical testing instruments are expected to see continued weak replacement demand. Dividend is expected at approximately 90 yen for the full year (up from 85 yen). Total assets were 43,161 million yen, and the equity ratio was 83.5%.

Importance:
Page Updated: October 29, 2026
IR Disclosure Date: October 29, 2026

Key Figures

  • Revenue: 14,284 million yen (Year-over-Year interim period +4.9%)
  • Operating Income: 2,150 million yen (Year-over-Year interim period +8.3%)
  • Ordinary Income: 2,185 million yen (Year-over-Year interim period approximately +8%)

AI要約

Business Performance Overview

In the second quarter of the fiscal year ending March 2027, revenue increased across the particle measurement instruments, medical devices, and environmental equipment segments. The particle measurement instruments segment is expected to see a substantial revenue increase due to firm semiconductor demand and data center expansion. Medical devices and hearing aids are expected to recover market-wise, but replacement demand remains subdued. Environmental equipment benefited from seismometer replacement projects and expansion in overseas markets. Total assets were approximately 43,160.6 million yen, and the equity ratio was 83.5%, indicating a solid financial foundation.

Outlook and Impact for Investors

In the second half, demand expansion for particle measurement instruments is expected, supporting revenue and profit growth. However, the performance of hearing aids and medical testing instruments could swing up or down depending on the timing of replacement demand recovery. The dividend is assumed to be 90 yen for the full year (indicating a potential upward revision from the prior year payout of 85 yen), suggesting continued improvement in shareholder returns.

Revenue Trend

Operating Income Trend

Segment Revenue Breakdown

Margin Analysis

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Rion Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →